Painchek Ltd · ASX:PCK
Painchek — Investor Presentation (July 2024)
41 slides from Painchek's investor presentation, Jul 30, 2024
Slide 1: Investor Webinar Presentation
ASX ANNOUNCEMENT 30 July 2024 INVESTOR WEBINAR PRESENTATION TUESDAY, 30 JULY 2024 Further to the webinar announcement on 26th July, PainChek® Ltd (ASX: PCK) (“PainChek®” or “the Company”), developer of the world’s first smart phone-based pain assessment and monitoring application, is pleased to prov
Slide 2: About PainChek
● Enhance engagement with GPs and allied healthcare professionals Clinical studies conducted in Australian and UK residential aged care centres have been published in various peer- reviewed journals including the Journal of Alzheimer’s Disease. An article in BMC Geriatrics indicates that PainChek® i
Slide 3: Quarterly Update July 2024
For personal use only July 2024 Quarterly PHILIP DAFFAS, CEO & MD PAINCHEK LTD | ASX:PCK 1 |
Slide 4: Our purpose is to give a voice to people who cannot verbalise pain
For personal use only Our purpose is to give a voice to people who cannot reliably verbalise their pain
Slide 5: The PainChek Universal App: quick and easy operation
THE PAINCHEK® UNIVERSAL APP: QUICK AND EASY OPERATION AI based micro-facial pain expression analysis: For personal use only A medical • 3 second scan of patient face device in • recognises 9 micro-facial expressions indicative of pain your pocket Guided Digital questionnaire checklist: • guides the
Slide 6: PainChek assessing facial indicators of pain
PAINCHEK® ASSESSING FACIAL INDICATORS OF PAIN PainChek’s AI analytics is based on Facial For personal use only Action Coding System (FACS) What is FACS? Guided Digital questionnaire checklist: • A catalogue of facial muscle movements that are indicative of facial expressions of pain (Action Units) •
Slide 7: PainChek is unique in using the validated FACS method
PAINCHEK® IS UNIQUE IN USING THE VALIDATED FACS METHOD TO ASSESS FACIAL INDICATORS OF PAIN PAINCHEK® ABBEY PAIN SCALE (UK, ANZ) Objective measures based on FACS research, both automated or carer guided assessment options plus Visuals provided for in- For personal use only assessment education. PAINA
Slide 8: The evolution of pain assessment
THE EVOLUTION OF PAIN ASSESSMENT Legacy Pain For personal use only PainChek® Assessment Tools “The PainChek app, which I see as a welcome evolutionary development of my past work, was introduced to improve pain management practices by ensuring an evidence-based assessment of pain could be made at th
Slide 9: The PainChek Universal App: unique pain profile for personalised care
THE PAINCHEK® UNIVERSAL APP: PROVIDES A UNIQUE PAIN PROFILE FOR PERSONALISED CARE AI based micro-facial pain expression analysis: For personal use only A medical • 3 second scan of patient face device in • recognises 9 micro-facial expressions indicative of pain your pocket Guided Digital questionna
Slide 10: How would you manage their pain?
HOW WOULD YOU MANAGE THEIR PAIN? John David For personal use only PainChek® Pain Score Pain intensity 0 to 6 No Pain 7 to 11 Mild Pain 77 years old, advanced 70 years old, advanced 12 to 15 Moderate Pain Alzheimer Dementia, Alzheimer Dementia, recent osteoarthritis, injury, unable to communicate pai
Slide 11: PainChek score example
For personal use only PainChek Score 14,\oderate wl APainChek score between 12 and 15 is classified as Moderate Pain The Voice D PainChek Inteligent Fain Introvert Verbally abusive Aggressive Fear or extreme dislike of touch, people Inappropriate behavior Confused Distressed Resisting care Prolonged
Slide 12: David
For personal use only David 10
Slide 13: PainChek pain profiling enables personalised pain management
PAINCHEK PAIN PROFILING ENABLES PERSONALISED PAIN MANAGEMENT John’s pain experience David’s pain experience For personal use only Advanced AD, osteoarthritis Advanced AD, recent injury MODERATE PAIN, MODERATE PAIN, INACTIVE - PROLONGED RESTING, VERBALLY ABUSIVE, AGGRESSIVE, FEAR OF TOUCH AND INTROVE
Slide 14: PainChek Analytics
PAINCHEK ANALYTICS REAL TIME INSIGHTS AT YOUR FINGERTIPS For personal use only PAINCHEK DIGITAL ANALYTICS SUPPORTS PERSON CENTRED PAIN MANAGEMENT 12
Slide 15: PainChek providing pain outcomes improvements
PAINCHEK PROVIDING PAIN OUTCOMES IMPROVEMENTS For personal use only SCOTTISH CARE ORCHARD CARE HOMES2 ORCHARD CARE HOMES2 INSPECTORATE1 PAIN MANAGEMENT MEDICATION MANAGEMENT • 100% increase in • Reduction in falls by • 33% reduction of frequency of pain 75% in 3 months (42% assessments antipsychotic
Slide 16: Abbey Healthcare – Motherwell Times article
ABBEY HEALTHCARE – MOTHERWELL TIMES ARTICLE July 2024 – coverage on PainChek in Scottish newspaper Motherwell Times re pilot at Abbeydale Court Care Home For personal use only “We’re thrilled with the impact the pilot has had already… (able to) reduce use of painkillers” – Manager at the home. “Ther
Slide 17: PainChek's three pillars of focus
PAINCHEK’S THREE PILLARS OF FOCUS For personal use only US market entry and Continued Direct to parent commercialisation – acceleration in market entry of the regulatory growth of PainChek Infant App submission pending Adult App in to target De Novo international clearance for late markets across 20
Slide 18: PainChek well positioned to exploit large global market opportunities
PAINCHEK WELL POSITIONED TO EXPLOIT LARGE GLOBAL MARKET OPPORTUNITES For personal use only AGED CARE MARKET HOME CARE INFANT MARKET HOSPITAL MARKET 6 MILLION BEDS 1 UP TO 10X AGED 400M PRE-VERBAL ~$1Bn ANNUALLY 4 & CARE MARKET 2 CHILDREN - 150M ANNUALLY TO $300M ANNUAL FIRST TIME PARENTS 3 ARR 2 1.
Slide 19: Continued global licences growth
CONTINUED GLOBAL LICENCES GROWTH For personal use only WW CONTRACTED LICENCES LICENCES / ARR $M $4.61 100,000 $4.30 $4.50 35% increase in ARR1 over the prior year 90,000 $3.90 $3.67 $4.00 80,000 $3.41 SAAS business model with 70-85% 70,000 $3.50 % gross margins2 on annual licences $3.00 60,000 $2.50
Slide 20: PainChek across Australia
PAINCHEK ACROSS AUSTRALIA AGED CARE’S MOST POPULAR DIGITAL CLINICAL TOOL Aged Care For personal use only PainChek commercial licences cover around 60,000 beds and 750 aged care homes, around 30% of total AU RAC market. Reseller agreement now established with BestMed medication management across Aged
Slide 21: PainChek's international expansion
PAINCHEK’S INTERNATIONAL EXPANSION For personal use only WW CONTRACTED LICENCES BY REGION 100,000 95,003 Strong commercial presence in ANZ, UK, and 90,000 90,023 Canada 85,368 80,000 77,037 30,380 36,163 70,000 25,073 Strong pipeline of beds in pilot programs and 70,007 19,367 contracts in negotiati
Slide 22: PainChek's growing UK footprint
PAINCHEK’S GROWING UK FOOTPRINT IN A 500,000 BED MARKET • PainChek commercial licences in UK aged care cover more than 35,000 beds and 1,000 care homes. For personal use only • 35 New RAC client contracts signed in the quarter , which include: - Salutem H/care – 1100 beds - Abbey Healthcare – 1,095
Slide 23: UK growth continues acceleration
UK GROWTH CONTINUES ACCELERATION IN 500,000 BED AGED CARE MARKET For personal use only UK CUSTOMER CONTRACTED LICENCES / ARR $M 40,000 36,163 35,000 30,380 93% increase in UK contracted beds to more than 36,000 beds across 800 homes over prior year 30,000 25,073 19,391 $1.9M ARR in UK when fully imp
Slide 24: Consistent growth in utility
CONSISTENT GROWTH IN UTILITY For personal use only Cumulative Number of PainChek® Assessments 7,000,000 5,990,000 Over 6 million to date global pain assessments 6,000,000 conducted on the PainChek platform 5,000,000 5,000,000 103% increase in global pain assessments 4,120,000 over the previous year
Slide 25: Integration partners provide access to 1,500,000 beds
PAINCHEK’S EXISTING CMS & MEDICATION MANAGEMENT AND INTEGRATION PARTNERS PROVIDE ACCESS TO 1,500,000 BEDS PainChek integrates and works with aged care management and medication management systems covering more than 180,000 For personal use only aged care beds in Australia, 25,000 beds in New Zealand
Slide 26: Market partnerships and drivers for USA & Canada
MARKET PARTNERSHIPS AND DRIVERS FOR USA & CANADA For personal use only PAINCHEK IS TARGETING FDA DE NOVO CLEARANCE AND US LAUNCH IN 2024 NORTH AMERICAN LONG TERM CARE PointClickCare: PainChek integrated MARKET OPPORTUNITY with PointClickCare leading long term care provider in USA & Canada – USA – 15
Slide 27: Poised for US FDA regulatory submission & market launch
POISED FOR US FDA REGULATORY SUBMISSION & MARKET LAUNCH For personal use only US FDA de Novo Validation Study data collection completed at all five clinical sites in Iowa & New York Clinical Investigation Report & associated FDA documentation scheduled to be completed in Q3 CY24 ; FDA de novo applic
Slide 28: PainChek around the world and across Australia
PAINCHEK AROUND THE WORLD….AND ACROSS AUSTRALIA Europe (EU) Canada For personal use only • Regulatory cleared & Patent secured • Regulatory cleared • Establishing commercial partner • Initial commercial contacts in major markets clients now • Ongoing research underpinning new implemented & products/
Slide 29: PainChek Infant progress
PAINCHEK INFANT PROGRESS TARGETING MARKET OF 400M PRE-VERBAL CHILDREN and 150 MILLION BORN EACH YEAR TO FIRST TIME PARENTS For personal use only Updated head movement Direct to Consumer New AI vocalisation Marketing feature feature • Updated adaptive • Completion of new • Australian market entry vid
Slide 30: Meet PainChek Infant
For personal use only Meet PainChek® Infant A PainChek Limited Product 28
Slide 31: Meet PainChek Infant
MEET PAINCHEK® INFANT The newest addition to the PainChek For personal use only family, PainChek Infant, is the world’s first AI-enabled app for instant pain assessment on infants aged 1-12 months. Designed for in-home use by parents or other non-medical carers, PainChek infant provides easy to use
Slide 32: Meet PainChek Infant
Meet PainChek® Infant For personal use only The newest addition to the PainChek family, PainChek Infant, is the world’s first AI-enabled app for instant pain assessment on infants aged 1-12 months. Designed for in-home use by parents or other non-medical carers, PainChek infant provides easy to use
Slide 33: Fresh identity with a clear link to PainChek Adult
FRESH IDENTITY WITH A CLEAR LINK TO PAINCHEK ADULT For personal use only • Unique, fresh colour palette to address the parent consumer market • Distinctly different to PainChek Adult brand, whilst keeping some elements aligned to create clear link (teal, logo) • Creative approach and messaging will
Slide 34: Early access registration now open
EARLY ACCESS REGISTRATION NOW OPEN • Over the next months, the PainChek Infant product will be available for use to a For personal use only selected group of parents in Australia • Eligible parents who sign up to the Early Access Program through the PainChek Infant website will be able to get pre- r
Slide 35: Marketing to drive acquisition & engagement
MARKETING TO DRIVE ACQUISITION & ENGAGEMENT Touchpoints: For personal use only Pregnancy to 12 months 1) Acquisition & Pregnancy Hospital At Home Out & About Medical Awareness: Dr appointment Blue Book Baby blogs Baby shops Immunisation Channel-Mix across the major Hospital Baby Bundle Podcasts Cafe
Slide 36: Partner network news
Partner network news! PainChek is excited to announce our first content partnership with Kiindred, an For personal use only “Education and lifestyle platform that is purpose built to help parents navigate pregnancy & parenthood with confidence” First Activity planned for August 2024 Target Audience
Slide 37: Corporate summary
CORPORATE SUMMARY For personal use only Top shareholders % Financial information Peters Investments Proprietary Ltd 8.3% Share price (29th July 2024) A$0.04 Founders 5.3% Shares on issue 1,635.8m Board & key staff 4.5% Market capitalisation AUD $65.4M Cash (30 June 2024) A$3.56M Unlisted options/per
Slide 38: The Team
THE TEAM For personal use only Philip Daffas Prof. Jeff Hughes Andrew Hoggan Iain McAdam CEO & Managing Chief Scientific Head of Operations CFO Director, MBA, BSc Officer PhD, MPS Philip is a highly accomplished Jeff is a professor in the Andy is a Psychologist, Iain has over 20 years finance & glob
Slide 39: The Board
THE BOARD For personal use only John Murray Philip Daffas Ross Harricks Adam Davey Cynthia Payne Non-Exec Chair CEO & Managing Non-Exec Director Non-Exec Director Non-Exec Director Director 25 years in tech & Philip is a highly Senior global medical Corporate finance 30 years executive Venture Capit
Slide 40: PainChek's three pillars of focus
PAINCHEK’S THREE PILLARS OF FOCUS For personal use only US market entry and Continued Direct to parent commercialisation – acceleration in market entry of the regulatory growth of PainChek Infant App submission pending Adult App in to target De Novo international clearance for late markets across 20
Slide 41: Contact
For personal use only Quarterly Update July 2024 CONTACT Philip Daffas, CEO & MD philip.daffas@painchek.com P A I N C H E K L T D | A S X : P C39 K